RxTrials Institute Drug Pipeline Alert

Sangamo BioSciences presented data from a Phase I clinical trial of a DNA-binding protein activator (ZFP-VEGF) in subjects with critical limb ischemia.

Applying the activator resulted in an increase in stem cells in the peripheral blood, the company said.

Bone marrow cells were examined before and after treatment in a subgroup. Data suggests that subjects who showed the most marked clinical improvements as judged by limb salvage, ulcer healing, reduction in pain and increased oxygen concentrations in the tissues also showed the greatest increase in bone marrow stem cells.